St.

Paul University Philippines

Tuguegarao City 3500 Cagayan

School of Nursing and Allied Health Sciences

College of Nursing

NCM 106 – PHARMACOLOGY

2 Semester, Academic Year 2021-2022
nd

WRITTEN TASK PERFORMANCE ASSIGNMENT (FINALS)

Instructions:

As we go discussing about drugs affecting the Respiratory System, Anti-infective, Anti-

inflammatory agents, Immunosuppressants and Immunizing agents, drugs affecting the
Gastrointestinal system and Miscellaneous drugs, you will be given the task of interviewing
one (1) of your family members and relatives who may members who have previously or
currently taking drugs under the concepts mentioned above. This task integrates Health
Assessment, Fundamentals of Nursing and Pharmacology.

This is an INDIVIDUAL assignment and you need to fill up the MODIFIED CASE and
DRUG STUDY TEMPLATE given below. The format is editable and will be used to
standardize submissions.

You are to submit the accomplished Case and Drug Study as a PDF file until June 21, 2022
at 5:00 PM. Your class facilitators will give you the link for submission. The ORAL
REVALIDA based on what you submitted will be scheduled later.

You may use any drug reference, pharmacology book or should you opt to take reference
from a website, follow the specifications of proper citation using an APA format. A sample
has been provided for you in a separate file.

/almarallag/v02/06.06.22
 St. Paul University Philippines
Tuguegarao City 3500 Cagayan

School of Nursing and Allied Health Sciences

College of Nursing

NCM 106 – PHARMACOLOGY

2 Semester, Academic Year 2021-2022
nd

WRITTEN TASK PERFORMANCE ASSIGNMENT

(FINAL PERIOD)
Patient’s Profile:

Patient’s Name (Initials) Mr. A.D

Age 37
Gender M
List of Medication/s
prescribed or taken 100 to 200 milligrams (mg) 2 times a day.

Prescribing Physician
(Use the Physician’s
Initial)
Past Health History
(Brief History)
S. A
Mr. A.D is a farmer and lives alone and due to being
independent he drinks too much alcohol and smoke too much
cigarettes. In his early age, he already complains for the pain
in his hands, difficulty breathing and sleeping, and joint
problem in his knees. He never went for check up but he took
some pain reliever without seeking advice from doctor.

Present Health History
(Brief History)
Mr. A.D experienced tenderness and pain. It commonly affects
the hands, knees or ankles, and usually the same joint on both
sides of the body, such as both hands or both knees. As soon as
he could not handle the pain anymore he gets for an accurate
diagnosis from the doctor. It was found that he has
rheumatoid arthritis. The doctor a started to interview him
and performed a physical examination. He was then given a
prescribed medicine for the treatment of his rheumatoid
arthritis.

Drug Study:

Generic Name of Drug:

Celebrex (celecoxib)

Drug Classification:

/almarallag/v02/06.06.22
NSAID, Analgesic (nonopioid), Specific COX-2 enzyme blocker

Drug Action/s: (1 point)

Celecoxib prevents the synthesis of a chemical called prostaglandin by inhibiting an

enzyme called cyclooxygenase 2 (COX-2). Prostaglandins are important mediators of pain
and inflammation in the body.

Dose, frequency and route of administration (doctor’s order): (1 point)

For rheumatoid arthritis or juvenile rheumatoid arthritis: Adults - 100 to 200 milligrams
(mg) 2 times a day.

Indication/s (reason/s) for administering the medication to the patient: (1 point)

Two (2) most common side-effects of the Two (2) most common adverse effects of the
medication (2 points) medication (2 points)

 headache  Abdominal pain, diarrhea, nausea,

 abdominal pain edema, dizziness, headache,
insomnia, upper respiratory tract
infections; rash.

 Potentially Fatal: Serious skin

reactions such as exfoliative
dermatitis, Stevens-Johnson
syndrome, and toxic epidermal
necrolysis.

List two (2) important nursing responsibilities you have to consider when administering the
medication: (2
points)

Assess patient for allergy to sulfonamides, aspirin, or NSAIDs. Patients with these allergies
should not receive celecoxib. Assess patient for skin rash frequently during therapy.
Discontinue at first sign of rash; may be life-threatening. SJS may develop. Treat
symptomatically; may recur once treatment is stopped.

Monitor for signs and symptoms of DRESS (fever, rash, lymphadenopathy, facial swelling)
periodically during therapy. Discontinue therapy if symptoms occur.

/almarallag/v02/06.06.22
List three (3) patient health teachings in relation to the medication: (3
points)

Instruct patient to take celecoxib as directed. Do not take more than prescribed dose.
Increasing doses does not appear to increase effectiveness. Advise patient to
read  Medication Guide  before starting therapy and with each Rx refill in case of changes.

Caution patient to avoid use of more than one NSAID or aspirin at a time; increases risk of
GI toxicity. Increasing dose or adding an NSAID or aspirin does not provide increased pain
relief but may increase incidence of side effects.

Advise patient to notify health care professional promptly if signs or symptoms of GI

toxicity (abdominal pain, black stools), skin rash, unexplained weight gain, or edema
occurs. Patients should discontinue celecoxib and notify health care professional if signs
and symptoms of hepatotoxicity (nausea, fatigue, lethargy, pruritus, jaundice, upper right
quadrant tenderness, flu-like symptoms) occur.

References:(followAPAformat) Silverstein FE, Faich G,

Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF,
Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity
with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid
arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety
Study. JAMA. 2000 Sep 13;284(10):1247-55.

Score: ___ /30

Evaluated by:

________________________________

/almarallag/v02/06.06.22
Name and Signature of Class Facilitator

Date evaluated: _________________________

/almarallag/v02/06.06.22